Caxton Associates (New York)’s Veradigm Inc. Common Stock MDRX Stock Holding History

Caxton Associates (New York)’s Portfolio MDRX Stock Details MDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-71,418	Closed	-$900K	–	635
2023 Q2	$900K	Buy	71,418 +57,881	+428%	+$703K	0.13%	165
2023 Q1	$177K	Buy	+13,537	New	+$219K	0.03%	431
2022 Q3	–	Sell	-10,752	Closed	-$159K	–	718
2022 Q2	$159K	Sell	10,752 -1,147	-10%	-$21.4K	0.02%	483
2022 Q1	$268K	Sell	11,899 -29,702	-71%	-$602K	0.02%	385
2021 Q4	$768K	Buy	+41,601	New	+$661K	0.08%	170
2021 Q3	–	Sell	-23,740	Closed	-$439K	–	633
2021 Q2	$439K	Buy	+23,740	New	+$400K	0.05%	205
2020 Q1	–	Sell	-17,395	Closed	-$171K	–	635
2019 Q4	$171K	Buy	+17,395	New	+$183K	0.02%	367

Other funds holding MDRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Caxton Associates (New York)'s MDRX Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Veradigm Inc. Common Stock (MDRX) in Q3 2023, closing a stake of 71,418 shares — an estimated $900K sold.

Caxton Associates (New York) first reported a position in MDRX in Q4 2019 and held it in 7 quarters. The position peaked at $900K in Q2 2023. 216 funds tracked by Wall St. Rank hold MDRX as of Q3 2023.

Caxton Associates (New York) reported no remaining Veradigm Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Caxton Associates (New York) sold 71,418 Veradigm Inc. Common Stock shares in Q3 2023, an estimated $900K.
Caxton Associates (New York) first reported a position in Veradigm Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Caxton Associates (New York)'s Veradigm Inc. Common Stock position peaked at $900K in Q2 2023.
216 funds tracked by Wall St. Rank held Veradigm Inc. Common Stock as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.